Stay up to date on the latest oncology and nursing conferences.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable MelanomaSeptember 13th 2022
The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
HRQOL Analysis of KEYNOTE-522 Supports Pembrolizumab Treatment for Triple-Negative Breast CancerSeptember 12th 2022
Patients with triple-negative breast cancer who received pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores compared with patients who received placebo.
Trastuzumab Deruxtecan Preserves Quality of Life in Patients With HR+, HER2-Low, Metastatic Breast CancerSeptember 12th 2022
A quality-of-life analysis of the pivotal Destiny-Breast04 trial showed that trastuzumab deruxtecan outperformed physician’s choice of treatment in delaying definitive deterioration.
Sacituzumab Govitecan Significantly Prolongs Overall Survival in Patients With HR+/HER2- Metastatic Breast CancerSeptember 10th 2022
Sacituzumab govitecan may represent a promising option for patients with endocrine resistant, hormone receptor–positive/HER2-negative metastatic breast cancer, according to updated findings from the phase 3 TROPiCs-02 study.
Satellite Clinical Trial Sites May Improve Minority Patient Accrual But Challenges Still ExistSeptember 8th 2022
Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.
Experimental Dosing Strategy With Sotorasib Plus Immunotherapy Helps Combat Hepatotoxicity in KRAS G12C+ NSCLCAugust 31st 2022
Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.
Prognostic Link Between pCR and Survival Outcomes May Be Key to Personalized Medicine Efforts in Early-Stage TNBCAugust 21st 2022
At the international congress on the Future of Breast Cancer West, Hope S. Rugo highlighted the predictive value of residual cancer burden scoring in ongoing research efforts to tailor triple-negative breast cancer treatments.
Podsada Discusses Biomarker Testing and ADC Therapies in Breast CancerAugust 16th 2022
The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.
Stephanie Jackson Unpacks Recent Advances in Leukemia TreatmentsAugust 15th 2022
Stephanie Jackson, DNP, MSN, RN, AOCNP, BMTCN, discusses the trajectory of targeted and CAR T-cell therapies such as ivosidenib and brexucabtagene autoleucel, and what nurses need to know about these treatments to be able to practice at the top of their licensure.
Amivantamab/Lazertinib/Chemo Regimen Gains Traction in EGFR-Mutant NSCLCAugust 13th 2022
Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.
Approaches to Urothelial Care Call for Nuanced AE ManagementAugust 11th 2022
Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting.
Evolution of Frontline VEGF TKI/Immunotherapy Treatments Propels Field of Renal Cell CarcinomaAugust 10th 2022
In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma.
Nurses Adapt to New Hematology Advances and Approvals in Leukemia TreatmentAugust 8th 2022
Treatments options for various histologies of leukemia are expanding with FDA approvals for drugs such as the combination of ivosidenib/azacitidine and the CAR T-cell therapy brexucabtagene autoleucel.